Immune checkpoint inhibitors of PD-L1 as cancer therapeutics

Since the discovery of immune checkpoint proteins, there has been a special interest in developing antibodies that block programmed cell death 1 receptor (PD-1) and programmed cell death receptor ligand 1 (PD-L1) for a subset of cancer patients. PD-1 signaling negatively regulates T cell-mediated im...

Descripción completa

Detalles Bibliográficos
Autores principales: Akinleye, Akintunde, Rasool, Zoaib
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6729004/
https://www.ncbi.nlm.nih.gov/pubmed/31488176
http://dx.doi.org/10.1186/s13045-019-0779-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6729004/
https://www.ncbi.nlm.nih.gov/pubmed/31488176
http://dx.doi.org/10.1186/s13045-019-0779-5

Ejemplares similares